Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

HRAS (Harvey rat sarcoma viral oncogene homolog)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Guardant360® CDx (54)

MSK-IMPACT (21)

Oncomine™ Dx Target Test (11)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

AnchorAIM® Personalized Treatment of Colorectal Cancer 11 Gene Test

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer® VariantPlex® Myeloid panel

Archer® VariantPlex® Solid Tumor Kit

Archer™ VARIANTPlex™ Complete Solid Tumor panel

Archer™ VARIANTPlex™ Pan Solid Tumor panel

Labcorp® Plasma Complete™

Liquid Trace™ Solid Tumor

LiquidHALLMARK®

NGS Targeted Hotspot Panel

NeoLAB® Solid Tumor Liquid Biopsy

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

OncoPanel™ Assay

OncoScreen™ Focus CDx Tissue Kit

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Tumor Mutation Load Assay

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio™ plasma resolve assay

PGDx elio™ tissue complete assay

SOPHiA DDM™ Myeloid Solution

SOPHiA DDM™ Solid Tumor Plus Solution

SOPHiA Myeloid Plus Solution

SafeSEQ HNSCC assay

SureSeq™ Pan-Myeloid Panel

Tempus xF Assay

ThyGeNEXT® + ThyraMIR®

TruSight Myeloid Sequencing Panel

TruSight Oncology Comprehensive

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

Guardant360® CDx (54)

MSK-IMPACT (21)

Oncomine™ Dx Target Test (11)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

AnchorAIM® Personalized Treatment of Colorectal Cancer 11 Gene Test

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer® VariantPlex® Myeloid panel

Archer® VariantPlex® Solid Tumor Kit

Archer™ VARIANTPlex™ Complete Solid Tumor panel

Archer™ VARIANTPlex™ Pan Solid Tumor panel

Labcorp® Plasma Complete™

Liquid Trace™ Solid Tumor

LiquidHALLMARK®

NGS Targeted Hotspot Panel

NeoLAB® Solid Tumor Liquid Biopsy

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

OncoPanel™ Assay

OncoScreen™ Focus CDx Tissue Kit

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Tumor Mutation Load Assay

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio™ plasma resolve assay

PGDx elio™ tissue complete assay

SOPHiA DDM™ Myeloid Solution

SOPHiA DDM™ Solid Tumor Plus Solution

SOPHiA Myeloid Plus Solution

SafeSEQ HNSCC assay

SureSeq™ Pan-Myeloid Panel

Tempus xF Assay

ThyGeNEXT® + ThyraMIR®

TruSight Myeloid Sequencing Panel

TruSight Oncology Comprehensive

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

›

RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	panitumumab Sensitive: A1 - Approval panitumumab Sensitive : A1	panitumumab Sensitive: A1 - Approval panitumumab Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	fruquintinib Sensitive: B - Late Trials fruquintinib Sensitive : B	fruquintinib Sensitive: B - Late Trials fruquintinib Sensitive : B
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
HRAS mutation	Urothelial Cancer	HRAS mutation	Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria bevacizumab + cetuximab Sensitive : C2	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria bevacizumab + cetuximab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria cetuximab + avelumab Sensitive : C2	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria cetuximab + avelumab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + camrelizumab Sensitive: C2 – Inclusion Criteria cetuximab + camrelizumab Sensitive : C2	cetuximab + camrelizumab Sensitive: C2 – Inclusion Criteria cetuximab + camrelizumab Sensitive : C2
HRAS G13R	Urothelial Cancer	HRAS G13R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3